Daewoong Pharmaceutical’s Olostar, a new combo drug that treats both high blood pressure and hyperlipidemia at the same time, is being introduced to the American market. The company announced that it signed an export contract of Olostar with Autotelic Inc. of the U.S.
Olostar is an ARB+Statin complex developed independently by Daewoong Pharmaceutical. It is the world's first drug consisting of Olmesatan of the ARB series and Rosuvastatin of the Statin series, which is how it is capable of treating both hypertension and dyslipidemia at the same time.
Autotelic Inc. is a biotechnology company that possesses both the basic devices to test therapeutic drug concentrations and the R&D experts to develop them. It also has experiences of successful clinical trials and developments of new drugs and incrementally modified drugs in the U.S.
The company will conduct the necessary clinical trials and developments of Olostar in the U.S. and release the drug in 2019. With the contract, Autotelic Inc. has secured the supply and circulation rights of Olostar in the U.S. and Canada.
Daewoong Pharmaceutical predicted that it will supply Olostar, worth about 300 billion won (US$272.41 million), for a decade after its release in the U.S. After its start in the U.S., the company is planning to introduce Olostar to the markets of more than 50 countries around the world.